Clovis takes PARP prostate cancer pole position with fast FD...

The FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate cancer, the first drug in this class to target the indication.

UK accounts for 12% of cell and gene therapy trials - report

The UK accounts for over 12% of global cell and gene therapy clinical trials, according to new data published by a government-backed agency.

Astellas to work with Adaptimmune to develop 'off the shelf'...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer.

GSK's CEO Walmsley aiming for six new approvals in 2020

GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year.

Experts call for review of innovative cancer therapies to bo...

There should be an independent review of how advances in cancer treatment are valued and paid for by the NHS and healthcare providers, according to a new policy report calling for improveme

AI specialist Exscientia signs drug discovery tie-up with Ba...